Enanta Pharmaceuticals Inc
ENTA16.100USD
-0.110-0.68%
Market hours （ET）Quotes delayed by 15 min
344.33MMarket Cap
LossP/E TTM
More Details of Enanta Pharmaceuticals Inc Company
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Enanta Pharmaceuticals Inc Info
Ticker SymbolENTA
Company nameEnanta Pharmaceuticals Inc
IPO dateMar 21, 2013
CEOLuly (Jay R)
Number of employees120
Security typeOrdinary Share
Fiscal year-endMar 21
Address4 Kingsbury Avenue
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16176070800
Websitehttps://www.enanta.com/
Ticker SymbolENTA
IPO dateMar 21, 2013
CEOLuly (Jay R)
Company Executives of Enanta Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
820.10K
-0.80%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
359.19K
-0.87%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
21.05K
-8.25%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Independent Director
Independent Director
--
--
Dr. Lesley Russell
Dr. Lesley Russell
Independent Director
Independent Director
--
--
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Independent Director
Independent Director
--
--
Mr. Scott T. Rottinghaus, M.D.
Mr. Scott T. Rottinghaus, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
820.10K
-0.80%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
359.19K
-0.87%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
21.05K
-8.25%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
18.31M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
7.35%
Krensavage Asset Management, LLC
7.33%
Janus Henderson Investors
6.75%
The Vanguard Group, Inc.
6.72%
BlackRock Institutional Trust Company, N.A.
5.44%
Other
66.41%
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
7.35%
Krensavage Asset Management, LLC
7.33%
Janus Henderson Investors
6.75%
The Vanguard Group, Inc.
6.72%
BlackRock Institutional Trust Company, N.A.
5.44%
Other
66.41%
Shareholder Types
Shareholders
Proportion
Investment Advisor
25.62%
Hedge Fund
24.08%
Investment Advisor/Hedge Fund
20.42%
Individual Investor
4.67%
Research Firm
0.91%
Family Office
0.13%
Bank and Trust
0.13%
Pension Fund
0.08%
Other
23.96%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
241
19.84M
81.86%
+1.48M
2025Q3
284
18.36M
116.72%
-107.60K
2025Q2
311
18.46M
118.85%
-252.82K
2025Q1
334
18.72M
123.57%
-7.64M
2024Q4
340
20.02M
119.82%
-1.32M
2024Q3
346
21.33M
132.40%
-905.26K
2024Q2
344
22.26M
134.58%
-675.35K
2024Q1
353
22.93M
127.70%
-4.09M
2023Q4
365
20.62M
117.32%
-18.18K
2023Q3
365
20.59M
115.82%
+45.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Farallon Capital Management, L.L.C.
2.12M
7.61%
--
--
Jun 30, 2025
Krensavage Asset Management, LLC
2.11M
7.58%
-2.14K
-0.10%
Jun 30, 2025
Janus Henderson Investors
523.74K
1.88%
+523.74K
--
Jun 30, 2025
The Vanguard Group, Inc.
1.98M
7.09%
-30.76K
-1.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.58M
5.66%
-143.12K
-8.32%
Jun 30, 2025
Millennium Management LLC
1.46M
5.23%
+111.66K
+8.29%
Jun 30, 2025
Acadian Asset Management LLC
867.04K
3.11%
--
--
Jun 30, 2025
Luly (Jay R)
826.73K
2.97%
+62.57K
+8.19%
Feb 12, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.7%
iShares Health Innovation Active ETF
0.11%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Biotechnology ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.7%
iShares Health Innovation Active ETF
Proportion0.11%
iShares Micro-Cap ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Enanta Pharmaceuticals Inc?
The top five shareholders of Enanta Pharmaceuticals Inc are:
Farallon Capital Management, L.L.C. holds 2.12M shares, accounting for 7.61% of the total shares.
Krensavage Asset Management, LLC holds 2.11M shares, accounting for 7.58% of the total shares.
Janus Henderson Investors holds 523.74K shares, accounting for 1.88% of the total shares.
The Vanguard Group, Inc. holds 1.98M shares, accounting for 7.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.58M shares, accounting for 5.66% of the total shares.
Farallon Capital Management, L.L.C. holds 2.12M shares, accounting for 7.61% of the total shares.
Krensavage Asset Management, LLC holds 2.11M shares, accounting for 7.58% of the total shares.
Janus Henderson Investors holds 523.74K shares, accounting for 1.88% of the total shares.
The Vanguard Group, Inc. holds 1.98M shares, accounting for 7.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.58M shares, accounting for 5.66% of the total shares.
What are the top three shareholder types of Enanta Pharmaceuticals Inc?
The top three shareholder types of Enanta Pharmaceuticals Inc are:
Farallon Capital Management, L.L.C.
Krensavage Asset Management, LLC
Janus Henderson Investors
Farallon Capital Management, L.L.C.
Krensavage Asset Management, LLC
Janus Henderson Investors
How many institutions hold shares of Enanta Pharmaceuticals Inc (ENTA)?
As of 2025Q4, 241 institutions hold shares of Enanta Pharmaceuticals Inc, with a combined market value of approximately 19.84M, accounting for 81.86% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -34.86%.
What is the biggest source of revenue for Enanta Pharmaceuticals Inc?
In FY2025Q3, the -- business generated the highest revenue for Enanta Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
